Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response - Concepedia

Concepedia

Publication | Closed Access

Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response

212

Citations

22

References

2022

Year

Sibylle Loibl, Jens Huober, Michael Braun, Julia Rey, Jens‐Uwe Blohmer, Jenny Furlanetto, D M Zahm, Claus Hanusch, Jörg Thomalla, Christian Jackisch,

Annals of Oncology

Neoadjuvant DurvalumabBreast OncologyMedicineImmunologyPathologyPathological Complete ResponseImmune Checkpoint InhibitorBreast CancerCancer TreatmentOncologyTumor Biology

References

	Year	Citations

Page 1

Page 1